background
DESCRIPTION
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. Background. Antiretroviral therapy (ART) has led to major improvements in the health of HIV infected populations - PowerPoint PPT PresentationTRANSCRIPT
Trends over calendar time in antiretroviral treatment success and failure in HIV
clinic populations
Background
• Antiretroviral therapy (ART) has led to major improvements in the health of HIV infected populations
• Key indicators of this success include the proportion of patients on therapy with viral load (VL) <50 copies/mL and the proportion of all patients with a low CD4 count (<200 /mm3)
• However, an increasing number of patients have experienced extensive triple class failure (ETCF)
Objectives
• To present trends over time in key indicators of treatment success and failure in the UK CHIC Study
• To estimate similar UK wide trends
Methods (1)
• The number of patients under follow-up in UK CHIC in each year from 2000-2008 was calculated
• Patients were defined to be ART experienced in a given year if they had started ART before July 1st
• The proportion of patients with CD4 count <200 cells/mm3 and VL <50 copies/mL on July 1st of each year was also calculated
Methods (2)
• Virologic failure of a drug was defined if a viral load >500 copies/mL was measured in an individual, despite at least 6 months of continuous use of the drug
• Extensive triple class failure (ETCF) was defined as failure of at least 3 NRTIs, an NNRTI and a PI/r
• CHIC estimates (risk group specific) were multiplied up to UK-wide estimates based on the breakdown of risk group from SOPHID
UK CHIC – 12 Centres
Centre Number of patientsBrighton 2,772Mortimer Market/Archway 5,904St. Mary’s 5,188Kings 3,461Chelsea and Westminster 10,286Barts and the London 3,717Royal Free 4,150Edinburgh Western General 1,012Homerton 1,247North Middlesex 1,494Bristol 1.026Leicester 625Number of patients included in dataset
- Before de-duplication 40,882- After de-duplication 35,377
Characteristics of cohort
n %
Total number of patients 35377 100.0
Sex: Female 8659 24.5
Risk group: MSM 17984 50.8IDU 1396 4.0Heterosexual 11149 31.5Other/not known 4848 13.7
Ethnicity: White 19912 56.3Black African 8543 24.2Other 4711 13.3Not known 2211 6.3
Median (IQR) age at first entry into cohort (years): 30 24-36
Patients under follow up in UK CHIC
2000 2001 2002 2003 2004 2005 2006 2007 2008
No. under follow-up 9008 10184 11359 12702 13915 15212 17022 17612 17023
% Male 83 81 80 78 77 76 76 76 76
% MSM 66 64 62 61 60 59 59 58 57% Heterosexual 23 26 28 30 31 32 32 33 32
ART experienced (N) 6977 7907 8775 9871 10924 11977 13566 14336 13993
% NNRTI experienced 64 72 76 78 81 81 80 79 81% PI experienced 63 59 57 54 55 56 56 58 56
% 3-class
experienced
35 38 38 38 39 39 39 39 38
Patients under follow up in UK CHIC
2000 2001 2002 2003 2004 2005 2006 2007 2008
No. under follow-up 9008 10184 11359 12702 13915 15212 17022 17612 17023
% Male 83 81 80 78 77 76 76 76 76
% MSM 66 64 62 61 60 59 59 58 57% Heterosexual 23 26 28 30 31 32 32 33 32
ART experienced (N) 6977 7907 8775 9871 10924 11977 13566 14336 13993
% NNRTI experienced 64 72 76 78 81 81 80 79 81% PI experienced 63 59 57 54 55 56 56 58 56
% 3-class
experienced
35 38 38 38 39 39 39 39 38
Patients under follow up in UK CHIC
2000 2001 2002 2003 2004 2005 2006 2007 2008
No. under follow-up 9008 10184 11359 12702 13915 15212 17022 17612 17023
% Male 83 81 80 78 77 76 76 76 76
% MSM 66 64 62 61 60 59 59 58 57% Heterosexual 23 26 28 30 31 32 32 33 32
ART experienced (N) 6977 7907 8775 9871 10924 11977 13566 14336 13993
% NNRTI experienced 64 72 76 78 81 81 80 79 81% PI experienced 63 59 57 54 55 56 56 58 56
% 3-class
experienced
35 38 38 38 39 39 39 39 38
Patients under follow up in UK CHIC
2000 2001 2002 2003 2004 2005 2006 2007 2008
No. under follow-up 9008 10184 11359 12702 13915 15212 17022 17612 17023
% Male 83 81 80 78 77 76 76 76 76
% MSM 66 64 62 61 60 59 59 58 57% Heterosexual 23 26 28 30 31 32 32 33 32
ART experienced (N) 6977 7907 8775 9871 10924 11977 13566 14336 13993
% NNRTI experienced 64 72 76 78 81 81 80 79 81% PI experienced 63 59 57 54 55 56 56 58 56
% 3-class
experienced
35 38 38 38 39 39 39 39 38
Patients under follow up in UK CHIC
2000 2001 2002 2003 2004 2005 2006 2007 2008
No. under follow-up 9008 10184 11359 12702 13915 15212 17022 17612 17023
% Male 83 81 80 78 77 76 76 76 76
% MSM 66 64 62 61 60 59 59 58 57% Heterosexual 23 26 28 30 31 32 32 33 32
ART experienced (N) 6977 7907 8775 9871 10924 11977 13566 14336 13993
% NNRTI experienced 64 72 76 78 81 81 80 79 81% PI experienced 63 59 57 54 55 56 56 58 56
% 3-class
experienced
35 38 38 38 39 39 39 39 38
Patients under follow up in UK CHIC
2000 2001 2002 2003 2004 2005 2006 2007 2008
No. under follow-up 9008 10184 11359 12702 13915 15212 17022 17612 17023
% Male 83 81 80 78 77 76 76 76 76
% MSM 66 64 62 61 60 59 59 58 57% Heterosexual 23 26 28 30 31 32 32 33 32
ART experienced (N) 6977 7907 8775 9871 10924 11977 13566 14336 13993
% NNRTI experienced 64 72 76 78 81 81 80 79 81% PI experienced 63 59 57 54 55 56 56 58 56
% 3-class
experienced
35 38 38 38 39 39 39 39 38
Patients under follow up in UK CHIC
2000 2001 2002 2003 2004 2005 2006 2007 2008
No. under follow-up 9008 10184 11359 12702 13915 15212 17022 17612 17023
% Male 83 81 80 78 77 76 76 76 76
% MSM 66 64 62 61 60 59 59 58 57% Heterosexual 23 26 28 30 31 32 32 33 32
ART experienced (N) 6977 7907 8775 9871 10924 11977 13566 14336 13993
% NNRTI experienced 64 72 76 78 81 81 80 79 81% PI experienced 63 59 57 54 55 56 56 58 56
% 3-class
experienced
35 38 38 38 39 39 39 39 38
Proportion of patients with current CD4 <200 cells/mmProportion of patients with current CD4 <200 cells/mm33 and and proportion of patients on HAART with VL<50 copies/mlproportion of patients on HAART with VL<50 copies/ml
0
10
20
30
40
50
60
70
80
90
100
2000 2001 2002 2003 2004 2005 2006 2007 2008
Year
Pro
po
rtio
n o
f p
ati
en
ts
On ART,VL<50copies/ml
CD4<200cells/mm
ART regimens received – all patients under follow upART regimens received – all patients under follow up
0
20
40
60
80
100
2000 2001 2002 2003 2004 2005 2006 2007 2008
Year
% o
f p
atie
nts
on
HA
AR
T
Sixth+
Fifth-line
Fourth-line
Third-line
Second-line
First-line
ART regimens received – ART regimens received – ART-naïve patients, CD4 >200 cells/mm3 at start
0
20
40
60
80
100
2000 2001 2002 2003 2004 2005 2006 2007 2008
Year
% o
f p
atie
nts
on
HA
AR
T
Sixth+
Fifth-line
Fourth-line
Third-line
Second-line
First-line
Estimated UK trends
Year 2000 2002 2004 2006 2008
No. under follow-up 20,384 28,265 37,999 47,723 56,433
On ART (N) 14,004 19,558 27,031 35,735 43,635
VL<50 copies/ml % 60 67 80 85 87
CD4<200 cells/mm3 % 20 15 13 10 7
ETCF (N) 132 483 985 1375 1829
Of which VL >50 copies/ml
%
24 24 40 49 58
Estimated UK trends
Year 2000 2002 2004 2006 2008
No. under follow-up 20,384 28,265 37,999 47,723 56,433
On ART (N) 14,004 19,558 27,031 35,735 43,635
VL<50 copies/ml % 60 67 80 85 87
CD4<200 cells/mm3 % 20 15 13 10 7
ETCF (N) 132 483 985 1375 1829
Of which VL <50 copies/ml
%
24 24 40 49 58
Estimated UK trends
Year 2000 2002 2004 2006 2008
No. under follow-up 20,384 28,265 37,999 47,723 56,433
On ART (N) 14,004 19,558 27,031 35,735 43,635
VL<50 copies/ml % 60 67 80 85 87
CD4<200 cells/mm3 % 20 15 13 10 7
ETCF (N) 132 483 985 1375 1829
Of which VL <50 copies/ml
%
24 24 40 49 58
Estimated UK trends
Year 2000 2002 2004 2006 2008
No. under follow-up 20,384 28,265 37,999 47,723 56,433
On ART (N) 14,004 19,558 27,031 35,735 43,635
VL<50 copies/ml % 60 67 80 85 87
CD4<200 cells/mm3 % 20 15 13 10 7
ETCF (N) 132 483 985 1375 1829
Of which VL <50 copies/ml
%
24 24 40 49 58
Estimated UK trends
Year 2000 2002 2004 2006 2008
No. under follow-up 20,384 28,265 37,999 47,723 56,433
On ART (N) 14,004 19,558 27,031 35,735 43,635
VL<50 copies/ml % 60 67 80 85 87
CD4<200 cells/mm3 % 20 15 13 10 7
ETCF (N) 132 483 985 1375 1829
Of which VL <50 copies/ml
%
24 24 40 49 58
Estimated UK trends
Year 2000 2002 2004 2006 2008
No. under follow-up 20,384 28,265 37,999 47,723 56,433
On ART (N) 14,004 19,558 27,031 35,735 43,635
VL<50 copies/ml % 60 67 80 85 87
CD4<200 cells/mm3 % 20 15 13 10 7
ETCF (N) 132 483 985 1375 1829
Of which VL <50 copies/ml
%
24 24 40 49 58
Estimated UK trends
Year 2000 2002 2004 2006 2008
No. under follow-up 20,384 28,265 37,999 47,723 56,433
On ART (N) 14,004 19,558 27,031 35,735 43,635
VL<50 copies/ml % 60 67 80 85 87
CD4<200 cells/mm3 % 20 15 13 10 7
ETCF (N) 132 483 985 1375 1829
Of which VL <50 copies/ml
%
24 24 40 49 58
ETCF in the UKETCF in the UK
0
200
400
600
800
1000
1200
1400
1600
1800
2000
Year under follow-up
Nu
mb
er
of
pa
tie
nts
ETCF,observed
VL<50copies/mL,observed
Summary
• ART success has improved markedly over the period 2000-2008 with around 87% of patients now having a VL <50 copies/mL
• Over 90% of all patients now have a CD4 count above the particularly high risk level of 200 cells/mm3
• The absolute number of patients with ETCF is increasing
• However, the proportion of such patients who have VL >50 copies/ml is decreasing so the absolute number of patients with ETCF and detectable virus is no longer increasing
Research Department of Infection and Population Health, UCL Medical School: Caroline Sabin, Teresa Hill, Loveleen Bansi, Andrew Phillips, Susie Huntington
Medical Research Council Clinical Trials Unit (MRC CTU): Abdel Babiker, David Dunn, Adam Glabay, Kholoud Porter
Brighton and Sussex University Hospitals NHS Trust : Martin Fisher, Duncan Churchill, Nicky Perry, Anthony Pullin
Chelsea and Westminster NHS Trust: Brian Gazzard, Steve Bulbeck, Jemima Clarke, Sundhiya Mandalia
Kings College London School of Medicine, GKT Hospitals: Frank Post, Philippa Easterbrook, Yasar Khan, Paragi Patel, Fatimah Karim, Stephen Duffell, Fowzia Ibrahim
Mortimer Market Centre, UCL Medical School: Richard Gilson, Shuk-Li Man, Ian Williams
Royal Free NHS Trust/UCL Medical School: Margaret Johnson, Clinton Chaloner, Helen Grabowska, Fiona Lampe, Dewi Ismajani Puradiredja, Mike Youle, Colette Smith
Imperial College Healthcare NHS Trust: John Walsh, Nicky Mackie, Alan Winston, Christian Kemble, Jonathan Weber
Barts and the London NHS Trust: Chloe Orkin, Kevin Jones, Rachel Thomas
Homerton University Hospital NHS Trust: Jane Anderson, Sajid Munshi
The Lothian University Hospital NHS Trust: Clifford Leen, Alan Wilson
North Middlesex University Hospital NHS Trust: Achim Schwenk, Jonathan Ainsworth
Health Protection Agency Centre for Infections: Valerie DelpechNorth Bristol NHS Trust: Mark Gompels, Debbie Dooley
UK CHIC is funded by the UK Medical Research Council
UK CHIC: Acknowledgements